2. Search Result
Search Result
Results for "

Major Histocompatibility Complex

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

8

Peptides

3

Inhibitory Antibodies

5

Recombinant Proteins

22

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3715
    OVA peptide
    2 Publications Verification

    		 MHC Inflammation/Immunology
    OVA peptide mainly exists in egg white, it is a class I (Kb)-restricted peptide epitope of ovalbumin presented by the class I MHC (major histocompatibility complex) molecule, H-2Kb (class I genes of the mouse MHC). OVA peptide has been widely studied in allergy research .
    OVA peptide
  • HY-P5499
    CMV pp65(13-27)

    		MHC Others
    CMV pp65(13-27) is a biological active peptide. (This peptide is derived from amino acid residues 13 to 27 of the 65k lower matrix phosphoprotein of the human cytomegalovirus. It contains a nine-amino-acid sequence (LGPISGHVL) that matches the consensus binding motif for a major histocompatibility complex H2-Dd T-cell epitope.)
    CMV pp65(13-27)
  • HY-P5410
    OVA-Q4 Peptide

    		MHC Others
    OVA-Q4 Peptide is a biological active peptide. (Q4 Peptide (SIIQFEKL) is a variant of the agonist ovalbumin (OVA) peptide (257-264), SIINFEKL. OVA Peptide is a class I (Kb)-restricted peptide epitope of ovalbumin presented by the class I MHC (major histocompatibility complex) molecule, H-2Kb (class I genes of the mouse MHC).)
    OVA-Q4 Peptide
  • HY-P990832
    Anti-MHC Class I Antibody (W6/32)

    		MHC Inflammation/Immunology
    Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human MHC Class I. Anti-MHC Class I Antibody (W6/32) reacts with the human major histocompatibility complex (MHC) class I, HLA-A, B, and C. Anti-MHC Class I Antibody (W6/32) increases adherence of monocytes to human endothelial cells. Anti-MHC Class I Antibody (W6/32) can be used for the research of immunology .
    Anti-MHC Class I Antibody (W6/32)
  • HY-179211
    CliMB-325

    		HSP MHC Cancer
    CliMB-325 is an HSP90 inhibitor that can induce MHC-I (EC50 = 498 nM) expression on the surface of CT26 murine colorectal cancer cells. CliMB-325 enhances T cell activation and exhibits lower toxicity. CliMB-325 can be used for the study of colorectal cancer .
    CliMB-325
  • HY-P4044
    HBV Seq2 aa:28-39

    		HBV Infection
    HBV Seq2 aa:28-39 is a HBsAg peptide, which binds to major histocompatibility complex (MHC) class I molecules .
    HBV Seq2 aa:28-39
  • HY-P10295
    p53 (232-240)

    		MDM-2/p53 Cancer
    p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .
    p53 (232-240)
  • HY-P992461
    SHR-1802

    		LAG-3 Cancer
    SHR-1802 is a humanized anti-LAG-3 monoclonal antibody.SHR-1802 specifically binds to LAG-3 and inhibits its binding to major histocompatibility complex class II (MHC-II), fibrinogen-like protein 1 (FGL1), galectin-3, and liver sinusoidal endothelial cell lectin.SHR-1802 can be used for the research of advanced solid tumors .
    SHR-1802
  • HY-P11280A
    PRAME peptide (425-433) acetate

    		Melanocortin Receptor Cancer
    PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma .
    PRAME peptide (425-433) acetate
  • HY-P11701
    SEIDLILGY

    		MHC Others
    SEIDLILGY is a nonapeptide identified as a peptide ligand derived from mouse major histocompatibility complex class I (MHC). SEIDLILGY serves as a tool chemical stimulant for the specific activation of sensory neurons expressing the particular vomeronasal receptor (V2rf2) .
    SEIDLILGY
  • HY-P991837
    Anti-HLA-DP Antibody (B7/21)

    		CD74 Inflammation/Immunology
    Anti-HLA-DP Antibody (B7/21) reacts with the class II major histocompatibility complex (MHC) antigen. Anti-HLA-DP Antibody (B7/21) recognizes a monomorphic determinant present on cells expressing DP1, DP2, DP3, DP4 and DP5. Recommend Isotype Controls: Mouse IgG3 kappa, Isotype Control (HY-P99985) .
    Anti-HLA-DP Antibody (B7/21)
  • HY-185260
    AA76-lipid

    		Liposome Cancer
    AA76-lipid (Compound aa76) is a compound with a C-terminal arginine and histidine. AA76-lipid can be used to prepare pancreas-targeted lipid nanoparticles AH-LNP. After assembling with proteins, the increased size of AH-LNP promotes Capsule-filter-mediated selective accumulation in the pancreas and receptor-mediated endocytosis, thereby enhancing pancreas-targeting ability. AA76-lipid enables highly pancreas-selective delivery of mRNA. AA76-lipid can be used in the research of pancreatic cancer .
    AA76-lipid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: